Get to know our clinical trials
Phase III, randomized, open-label clinical trial of ZL-1310, a DLL3-targeted antibody-drug conjugate (ADC), compared with investigator’s choice of therapy in participants with relapsed small cell lung cancer.
THE OBJECTIVE IS TO STUDY THE SAMPLES TO UNDERSTAND THEIR RESPONSES TO THE STUDY DRUG AND TO OBTAIN MORE INFORMATION ABOUT SMALL CELL LUNG CANCER.
Specialist
Medical Oncology Department
Navarre headquarters
Technical Summary
- PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF ZL-1310, A DLL3-TARGETED ANTIBODY-DRUG CONJUGATE (ADC), COMPARED WITH INVESTIGATOR’S CHOICE OF THERAPY IN PARTICIPANTS WITH RELAPSED SMALL CELL LUNG CANCER.
- Code EudraCT: 2025-522818-23
- Protocol number: ZL-1310-003
- Promoter: Zai Lab (US) LLC
- Molecule/Drug: ZL-1310
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.